We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Customized Monoclonal Antibody Design Highlighted at the AACC Clinical Lab Expo

By LabMedica International staff writers
Posted on 31 Jul 2013
Print article
Image: Customized monoclonal antibodies by MedixMAB by Design (Photo courtesy of Medix Biochemica).
Image: Customized monoclonal antibodies by MedixMAB by Design (Photo courtesy of Medix Biochemica).
Biotech researchers and other life scientists working with monoclonal antibodies (MABs) who are attending the AACC (American Association for Clinical Chemistry) Clinical Lab Expo in Houston (TX, USA), from July 30-August 1, 2013, are invited to learn how to exploit the services of an innovative developer and producer of custom-made recombinant antibodies.

Medix Biochemica (Kauniainen, Finland), producer of monoclonal antibodies for the global IVD industry and of proprietary rapid diagnostic tests, is highlighting its MedixMAB by Design antibody production service at the Clinical Lab Expo.

By offering a completely customized service for the in vitro generation of high-performance monoclonal recombinant antibodies and Fab fragments, MedixMAB by Design paves the way for the development of superior IVD assays. Antibodies are produced to the strictest international quality standards, and this new service gives IVD manufacturers access to topflight biological without the need to invest in costly production facilities and expertise.

Medix makes monoclonal antibodies using an advanced in vitro system, which incorporates the latest in cutting-edge phage display-production technology. These antibodies can target a broad range of antigens, including poorly immunoreactive and toxic compounds. Successful recombinant antibodies can then easily be produced in bulk quantities. Alternatively, Fab fragments, which greatly enhance specificity and sensitivity of solid-phase IVD assays, can be generated in just three months. All development and manufacturing processes are comprehensively regulated and documented, adhering to ISO 9001, ISO 13485 and [US] FDA QSR quality standards.

Maija Partanen, product manager for MedixMAB by Design, said, “With 30 years of experience in antibody production technology, Medix Biochemica provides the IVD industry with outstanding diagnostic performance. Our fast and flexible, quality-assured MedixMAB by Design service enables IVD manufacturers to offer the next generation of IVD assay, with superior sensitivity and specificity, at minimal cost.”

Related Links:

Medix Biochemica



New
Platinum Supplier
Respiratory Virus Multiplex Test
Respiratory Virus 12 Types Nucleic Acid Detection Kit
New
Anti-HIV 1/2 ELISA Test
HIV 1/2 Antibody (3rd) Test Kit (ELISA)
New
Capillary Electrophoresis System
CAPILLARYS 3 DBS
New
Whole Blood Control
ESR-Chex Plus

Print article
IIR Middle East

Channels

Technology

view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.